Robert Torregrosa1, Xiao-Fang Yang2, Erik T Dustrude3, Theodore R Cummins4, Rajesh Khanna2, Harold Kohn5. 1. NeuroGate Therapeutics, Inc., 150 Fayetteville Street, Suite 2300, Raleigh, NC 27601, United States. 2. Department of Pharmacology and Neuroscience Graduate Interdisciplinary Program, College of Medicine, University of Arizona, Tucson, AZ 85742, United States. 3. Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, United States. 4. Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, United States; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, United States. 5. NeuroGate Therapeutics, Inc., 150 Fayetteville Street, Suite 2300, Raleigh, NC 27601, United States; Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States; Department of Chemistry, University of North Carolina, Chapel Hill, NC 27599, United States.
Abstract
Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology for their anticonvulsant activities in animal seizure models and for their sodium channel activities. We found compounds with various substituents at the terminal aromatic ring that had excellent anticonvulsant activity. Of these compounds, (R)-N-4'-((3″-chloro)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-5) and (R)-N-4'-((3″-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-9) exhibited high protective indices (PI=TD50/ED50) comparable with many antiseizure drugs when tested in the maximal electroshock seizure test to mice (intraperitoneally) and rats (intraperitoneally, orally). Most compounds potently transitioned sodium channels to the slow-inactivated state when evaluated in rat embryonic cortical neurons. Treating HEK293 recombinant cells that expressed hNaV1.1, rNaV1.3, hNaV1.5, or hNaV1.7 with (R)-9 recapitulated the high levels of sodium channel slow inactivation.
Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology n class="Chemical">for their anticonvulsant activities in animal seizure models and for their sodium channel activities. We found compounds with various substituents at the terminal aromatic ring that had excellent anticonvulsant activity. Of these compounds, (R)-N-4'-((3″-chloro)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-5) and (R)-N-4'-((3″-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-9) exhibited high protective indices (PI=TD50/ED50) comparable with many antiseizure drugs when tested in the maximal electroshock seizure test to mice (intraperitoneally) and rats (intraperitoneally, orally). Most compounds potently transitioned sodium channels to the slow-inactivated state when evaluated in rat embryonic cortical neurons. Treating HEK293 recombinant cells that expressed hNaV1.1, rNaV1.3, hNaV1.5, or hNaV1.7 with (R)-9 recapitulated the high levels of sodium channel slow inactivation.
Authors: Yuying Wang; Ki Duk Park; Christophe Salome; Sarah M Wilson; James P Stables; Rihe Liu; Rajesh Khanna; Harold Kohn Journal: ACS Chem Neurosci Date: 2011-02-16 Impact factor: 4.418
Authors: Thomas Stöhr; Harvey J Kupferberg; James P Stables; Daeock Choi; Robert H Harris; Harold Kohn; Nancy Walton; H Steve White Journal: Epilepsy Res Date: 2007-04-12 Impact factor: 3.045
Authors: Christophe Salomé; Elise Salomé-Grosjean; Ki Duk Park; Pierre Morieux; Robert Swendiman; Erica DeMarco; James P Stables; Harold Kohn Journal: J Med Chem Date: 2010-02-11 Impact factor: 7.446
Authors: Katarzyna Pańczyk; Dorota Żelaszczyk; Paulina Koczurkiewicz; Karolina Słoczyńska; Elżbieta Pękala; Ewa Żesławska; Wojciech Nitek; Paweł Żmudzki; Henryk Marona; Anna Waszkielewicz Journal: Medchemcomm Date: 2018-10-19 Impact factor: 3.597